ConvaTec Group Plc (LON:CTEC) is very pleased to announce the appointment of Karim Bitar as Chief Executive Officer with an effective date of 30 September, 2019.
Since 2011, Karim Bitar has been Chief Executive Officer of Genus Plc, a leading global agricultural biotechnology company focused on animal genetics which is listed on the London Stock Exchange. Karim helped transform Genus, creating three global business units and successfully expanding the company’s presence in key emerging markets. He also increased substantially the company’s investment in R&D, creating a strong pipeline of innovative products. During Karim’s tenure as CEO of Genus, shareholder returns increased by over 150%.
Prior to Genus, Karim spent 15 years in various roles with increasing responsibility at Eli Lilly where from 2008 he was President of Europe, Australia and Canada, leading an organisation with annual sales of approximately US$5 billion per year.
Sir Christopher Gent, Chairman of ConvaTec, said:
“I am delighted to announce Karim’s appointment as Chief Executive Officer of ConvaTec. He is an experienced and highly regarded leader with an excellent track record of delivering impressive results and transformational change within similar businesses. The Board and I are very confident that Karim is the right person to lead ConvaTec through the next stage of the Company’s development.”
Karim Bitar said:
“ConvaTec competes in attractive chronic care markets and has a solid portfolio of products and services. I am excited by the opportunity to lead ConvaTec to stronger and sustainable rates of profitable growth. ConvaTec has the potential to achieve market leadership across its franchises, by focusing on innovation and execution excellence and by leveraging its global presence.”
